Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatmen
- PDF / 343,797 Bytes
- 9 Pages / 595.28 x 793.7 pts Page_size
- 96 Downloads / 171 Views
ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY
RESEARCH
Open Access
Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/ salmeterol combination treatment in subjects with persistent asthma David I Bernstein1*, Jacques Hébert2, Amarjit Cheema3, Kevin R Murphy4, Ivan Chérrez-Ojeda5, Carlos Eduardo Matiz-Bueno6, Wen-Ling Kuo7 and Hendrik Nolte7
Abstract Background: Mometasone furoate/formoterol (MF/F) is a novel combination therapy for treatment of persistent asthma. This noninferiority trial compared the effects of MF/F and fluticasone propionate/salmeterol (FP/S) combination therapies on pulmonary function and onset of action in subjects with persistent asthma. Methods: Following a 2- to 4-week run-in period with MF administered via a metered-dose inhaler (MDI) 200 μg (delivered as 2 inhalations of MF-MDI 100 μg) twice daily (BID), subjects (aged ≥12 y) were randomized to MF/FMDI 200/10 μg BID (delivered as 2 inhalations of MF/F-MDI 100/5 μg) or FP/S administered via a dry powder inhaler (DPI) 250/50 μg (delivered as 1 inhalation) BID for 12 weeks. The primary assessment was change from baseline to week 12 in area under the curve for forced expiratory volume in 1 second measured serially for 0-12 hours postdose (FEV1 AUC0-12 h). Secondary assessments included onset of action (change from baseline in FEV1 at 5 minutes postdose on day 1) and patient-reported outcomes. Results: 722 subjects were randomized to MF/F-MDI (n = 371) or FP/S-DPI (n = 351). Mean FEV1 AUC0-12 h change from baseline at week 12 for MF/F-MDI and FP/S-DPI was 3.43 and 3.24 L × h, respectively (95% CI, -0.40 to 0.76). MF/F-MDI was associated with a 200-mL mean increase from baseline in FEV1 at 5 minutes postdose on day 1, which was significantly larger than the 90-mL increase for FP/S-DPI (P < 0.001). The overall incidence of adverse events during the 12-week treatment period that were considered related to study therapy was similar in both groups (MF/F-MDI, 7.8% [n = 29]; FP/S-DPI, 8.3% [n = 29]). Conclusions: The results of this 12-week study indicated that MF/F improves pulmonary function and asthma control similar to FP/S with a superior onset of action compared with FP/S. Both drugs were safe, improved asthma control, and demonstrated similar results for other secondary study endpoints. Trial registration: ClinicalTrials.gov: NCT00424008 Keywords: asthma, mometasone furoate/formoterol, fluticasone propionate/salmeterol, noninferiority, onset of action
* Correspondence: [email protected] 1 Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA Full list of author information is available at the end of the article © 2011 Bernstein et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Bernstein
Data Loading...
